FindTrial
Sign In

Randomized controlled trial of a comparison between ritonavir-boosted atazanavir with tenofovir plus emtricitabine versus rilpivirine with tenofovir plus emtricitabine in occupational post-exposure prophylaxis for HIV infection

Randomized controlled trial of a comparison between ritonavir-boosted atazanavir with tenofovir plus emtricitabine versus rilpivirine with tenofovir plus emtricitabine in occupational post-exposure prophylaxis for HIV infection

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20190311001
Enrollment
Unknown
Registered
2019-03-11
Start date
2018-01-09
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Occupational post&#45

Interventions

Tenofovir/Emtricitabine (300/200) + Rilpivirine (25),Tenofovir/Emtricitabine (300/200) + Ritonavir&#45
boosted atazanavir (300/100)
Active Comparator Drug,Experimental Drug
TDF/FTC+RPV,TDF/FTC+ATV/r

Sponsors

King Chulalongkorn Memorial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: >18-year-old of age occupational exposure to HIV less than 72 hours

Exclusion criteria

Exclusion criteria: non-occupational exposure to HIV allergic to study drugs HIV-negative source

Design outcomes

Primary

MeasureTime frame
Completion rate 28 days after initiation of intervention Chi-square test—

Secondary

MeasureTime frame
Adherence 28 days after initiation of intervention Chi square test,Side effects 28 days after initiation of intervention Chi square test,Change of total bilirubin level 28 days after initiation of intervention student t-test,Seroconversion 28 days & 90 days after initiation of intervention Chi square test—

Countries

Thailand

Contacts

Public ContactPreut Assawaworrarit

Unaffiliated

micro.preut@gmail.com022564000

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026